Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Importance Prostate cancer is the most common cancer diagnosis made in men with more
than 160 000 new cases each year in the United States. Although it often has an indolent …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Background The optimal timing of radiotherapy after radical prostatectomy for prostate
cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy …

Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …

Purpose To report the primary endpoint of biochemical progression-free survival (b-PFS)
and secondary survival endpoints from ASCENDE-RT, a randomized trial comparing 2 …

Background Adding abiraterone acetate with prednisolone (AAP) or docetaxel with
prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy …

Prostate cancer (PCa) incidence and mortality have rapidly increased in China. Notably,
unique epidemiological characteristics of PCa are found in the Chinese PCa population …

Background Results from large randomised controlled trials combining docetaxel or
bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged …

Emerging data demonstrate homologous recombination (HR) defects in castration-resistant
prostate cancers, rendering these tumours sensitive to PARP inhibition. Here we …